GATA-3 INHIBITORS INTENDED FOR USE IN THE TREATMENT OF TH2-BASED ASTHMA

MA40739AUndetermined Publication Date: 2016-11-16STERNA BIOLOGICALS GMBH & CO KG

0 Cites 0 Cited by

Patent Information

Application Number: MA40739
Authority / Receiving Office: MA · MA
Patent Type: Applications
Current Assignee / Owner
Filing Date: 2015-05-15
Publication Date: 2016-11-16

Application Information

Patent Timeline

15 May 2015

Application

MA40739

16 Nov 2016

Publication

MA40739A

IPC: A61P11/06

Inventors: Bille Joachim; Renz Jonas

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Patent Text Reader

Abstract

The invention relates to gata-3 inhibitors for use in the treatment of th2-based asthma, in particular gata-3 directed enzymes for use in the treatment of a patient with allergic asthma, wherein the patient is characterized by (i) a blood eosinophil count of 3% or more, in particular 4% or more, more particularly 5% or more; and / or (ii) a blood eosinophil count of 350 x 10⁶ / l or more, in particular 450 x 10⁶ / l or more; and / or (iii) fractionated expiratory nitric oxide of 40 ppb or more.

Need to check novelty before this filing date? Find Prior Art